154 related articles for article (PubMed ID: 15910011)
21. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.
Boulton DW; Li L; Frevert EU; Tang A; Castaneda L; Vachharajani NN; Kornhauser DM; Patel CG
Clin Pharmacokinet; 2011 Apr; 50(4):253-65. PubMed ID: 21348538
[TBL] [Abstract][Full Text] [Related]
22. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
[TBL] [Abstract][Full Text] [Related]
23. Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant.
Landry I; Aluri J; Hall N; Filippov G; Dayal S; Moline M; Reyderman L
Pharmacol Res Perspect; 2021 Apr; 9(2):e00734. PubMed ID: 33689224
[TBL] [Abstract][Full Text] [Related]
24. Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation.
Bubalo JS; Cherala G; McCune JS; Munar MY; Tse S; Maziarz R
J Clin Pharmacol; 2012 Apr; 52(4):586-94. PubMed ID: 21415280
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease.
Krishnaswami S; Chow V; Boy M; Wang C; Chan G
J Clin Pharmacol; 2014 Jan; 54(1):46-52. PubMed ID: 24030917
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
Parasrampuria DA; Marbury T; Matsushima N; Chen S; Wickremasingha PK; He L; Dishy V; Brown KS
Thromb Haemost; 2015 Apr; 113(4):719-27. PubMed ID: 25566930
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity.
Shadle CR; Lee Y; Majumdar AK; Petty KJ; Gargano C; Bradstreet TE; Evans JK; Blum RA
J Clin Pharmacol; 2004 Mar; 44(3):215-23. PubMed ID: 14973304
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of aliskiren in patients with end-stage renal disease undergoing haemodialysis.
Khadzhynov D; Slowinski T; Lieker I; Neumayer HH; Albrecht D; Streefkerk HJ; Rebello S; Peters H
Clin Pharmacokinet; 2012 Oct; 51(10):661-9. PubMed ID: 23018529
[TBL] [Abstract][Full Text] [Related]
29. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.
Aweeka F; Jayesekara D; Horton M; Swan S; Lambrecht L; Wilner KD; Sherwood J; Anziano RJ; Smolarek TA; Turncliff RZ
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):27S-33S. PubMed ID: 10771451
[TBL] [Abstract][Full Text] [Related]
30. Dose-finding study of rivaroxaban in hemodialysis patients.
De Vriese AS; Caluwé R; Bailleul E; De Bacquer D; Borrey D; Van Vlem B; Vandecasteele SJ; Emmerechts J
Am J Kidney Dis; 2015 Jul; 66(1):91-8. PubMed ID: 25804678
[TBL] [Abstract][Full Text] [Related]
31. Venetoclax pharmacokinetics in participants with end-stage renal disease undergoing haemodialysis.
Noorani B; Menon RM; Chen X; Marsh KC; Huang W; Gupta S; Dobkowska E; Marbury T; Salem AH
Br J Clin Pharmacol; 2024 Mar; 90(3):748-758. PubMed ID: 37855131
[TBL] [Abstract][Full Text] [Related]
32. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.
Massaro AM; Lenz KL
Ann Pharmacother; 2005 Jan; 39(1):77-85. PubMed ID: 15562136
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment.
Shimasaki Y; Sakaki M; Itou M; Kobayashi T; Aso M; Kagawa T; Saiki T; Matsuno K; Sano Y; Shimizu K; Kuroda S; Koumura E
Clin Drug Investig; 2018 Nov; 38(11):1041-1051. PubMed ID: 30194585
[TBL] [Abstract][Full Text] [Related]
34. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
Gore L; Chawla S; Petrilli A; Hemenway M; Schissel D; Chua V; Carides AD; Taylor A; Devandry S; Valentine J; Evans JK; Oxenius B;
Pediatr Blood Cancer; 2009 Feb; 52(2):242-7. PubMed ID: 18985740
[TBL] [Abstract][Full Text] [Related]
35. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe.
Majumdar AK; McCrea JB; Panebianco DL; Hesney M; Dru J; Constanzer M; Goldberg MR; Murphy G; Gottesdiener KM; Lines CR; Petty KJ; Blum RA
Clin Pharmacol Ther; 2003 Aug; 74(2):150-6. PubMed ID: 12891225
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function.
Berg JK; Tzanis E; Garrity-Ryan L; Bai S; Chitra S; Manley A; Villano S
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158281
[TBL] [Abstract][Full Text] [Related]
37. Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist.
Bauman JW; Antal JM; Adams LM; Johnson BM; Murray SC; Peng B; Kirby LC; Lebowitz PF; Marbury TC; Swan S; Gutierrez M
Invest New Drugs; 2012 Apr; 30(2):662-71. PubMed ID: 21188466
[TBL] [Abstract][Full Text] [Related]
38. The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma.
Egerer G; Eisenlohr K; Gronkowski M; Burhenne J; Riedel KD; Mikus G
Br J Clin Pharmacol; 2010 Dec; 70(6):903-7. PubMed ID: 21175446
[TBL] [Abstract][Full Text] [Related]
39. Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
Groenendaal-van de Meent D; Kerbusch V; Kaspera R; Barroso-Fernandez B; Galletti P; Klein GK; den Adel M
Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):141-153. PubMed ID: 33165773
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease.
Kosoglou T; Kraft WK; Kumar B; Statkevich P; Xuan F; Ma L; Jennings LK; Schiller JE; Langdon RB; Cutler DL
Eur J Clin Pharmacol; 2012 Jul; 68(7):1049-56. PubMed ID: 22315147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
